Brand Intelligence Graph
Company Overview
About PhaseV
PhaseV is an AI clinical trial platform that uses predictive analytics to optimize trial design, site selection, patient enrollment, and protocol adherence — delivering dramatic efficiency improvements over traditional trial execution. The company raised $50 million in Series A financing in May 2025 co-led by Accel and Insight Partners, and entered 2026 with 40+ global pharmaceutical sponsors as customers including 7 of the world's top pharmaceutical companies.
Business Model & Competitive Advantage
The platform's reported outcomes are compelling: 50% reduction in trial costs, 40% reduction in enrollment size required, and 40% reduction in trial duration. For a pharmaceutical company running a Phase 3 trial that would otherwise cost $500 million and take 5 years, these improvements represent $250 million in savings and 2 years of development time — potentially worth $2-3 billion in earlier market exclusivity.
Competitive Landscape 2025–2026
In 2026, the company reports that biopharma is shifting from AI pilot programs to full-scale execution — adoption is moving from innovation teams to core clinical operations. This inflection from piloting to procurement represents the kind of enterprise buying pattern that precedes accelerated revenue growth. PhaseV's proprietary datasets from completed trials create a compounding data advantage that improves its predictive models with each additional trial.
Key Differentiators
Emerging Innovator
PhaseV is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare PhaseV with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from PhaseV? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim PhaseV Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention PhaseV vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →